Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Name: Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Published: 2026
License: Public Domain

Novartis Pharmaceuticals · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

breast-cancer prostate-cancer

advanced hr+/her2- breast cancer, advanced ccne1-amplified solid tumors, metastatic castration-resistant prostate cancer (mcrpc), erw316, fulvestrant, letrozole, hormone receptor positive, her-2 negative, breast cancer, ccne1 amplification, prostate cancer, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Related documents